Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Context Therapeutics Inc. Context Therapeutics Reports First Quarter 2024 Operating and Financial Results May 08, 2024 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 May 02, 2024 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics Announces $100 Million Private Placement May 02, 2024 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers April 01, 2024 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics Reports Full Year 2023 Operating and Financial Results March 21, 2024 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results November 09, 2023 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76 October 31, 2023 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting September 27, 2023 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results August 09, 2023 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics to Participate in Two August 2023 Investor Conferences August 01, 2023 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics Reports First Quarter 2023 Operating and Financial Results May 10, 2023 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics to Participate in Two April 2023 Investor Conferences April 03, 2023 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates March 22, 2023 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 March 15, 2023 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer February 06, 2023 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer January 31, 2023 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers January 09, 2023 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones January 04, 2023 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer December 08, 2022 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors November 29, 2022 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium November 21, 2022 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results November 09, 2022 From Context Therapeutics Inc. Via GlobeNewswire Tickers CNTX Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.